A2A Wins AI Quickfire

Updated: Feb 7, 2020

A2A Wins AI Quickfire Challenge at JLABS @ Toronto

LEARN MORE

Recent Posts

See All

A2A co-founded biomea Fusion raises $56M

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of

A2A / Daewoong Pharmaceutical Oncology Agreement

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery. LEARN MORE

A2A Appoints New Advisors

Dr. Siddhartha Mukherjee, Dr. Annalisa Jenkins and Dr. Srikumar Chellappan join A2A’s Advisory Board. LEARN MORE